Completed PHASE2 INTERVENTIONAL 2-arm NCT03423823

Ziv-aflibercept Efficacy in Better Regulating AMD (ZEBRA)

An Active-treatment Study of the Efficacy of Ziv-aflibercept in Patients With Neovascular Age-Related Macular Degeneration

Sponsor: Kapil Kapoor

Conditions Wet Age-related Macular Degeneration Wet Macular Degeneration

Interventions Ranibizumab Ziv-Aflibercept 25 MG/ML [Zaltrap]

Updated 7 times since 2018 Last updated: Oct 5, 2020 Started: Jul 7, 2017 Primary completion: Jun 26, 2020 Completion: Jun 26, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Wet Age-related Macular Degeneration and Wet Macular Degeneration, this trial is completed. The trial is conducted by Kapil Kapoor and has accumulated 7 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Nov 2020 — Jan 2021 [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed
Nov 2019 — Nov 2020 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting

▶ Show 2 earlier versions

Jun 2018 — Nov 2019 [monthly]

Recruiting PHASE2
Mar 2018 — Jun 2018 [monthly]

Recruiting PHASE2

First recorded

Jul 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Kapil Kapoor

Data source: Wagner Macula & Retina Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Virginia Beach, United States